Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Skin Neoplasms 2Melanoma 2Uveal Melanoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Eye Neoplasms 1Esophageal Neoplasms 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Peptides × Clear all
NCT00254397 2019-10-16

Melanoma Vaccine With Peptides and Leuprolide

M.D. Anderson Cancer Center

Phase 2 Completed
98 enrolled 11 charts
Dermatologic

Uveal Melanoma, Eye Neoplasms, Melanoma, Skin Neoplasms

NCT00923195 2015-10-28

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
4 enrolled 11 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡